Zivo Bioscience, INC 8-K filings

ZIVO Bioscience will file Form 15 to suspend SEC reporting and voluntarily delist from OTC markets as part of cost cuts, with its interim CFO and a director resigning.

ZIVO Bioscience announces the immediate resignation of its CFO, Keith R. Marchiando, and the appointment of William A. Sullivan as Interim CFO.

ZIVO Bioscience's CEO highlights significant progress in human nutrition and animal health, driven by proprietary algae technology with superior antioxidant activity and immune-modulating effects.

ZIVO Bioscience announces the immediate resignation of Board Director Nola Masterson, who chaired the Nominating and Governance committee.

Zivo Bioscience, Inc. has commenced a new convertible debt offering to raise up to $2,000,000, issuing an initial bridge promissory note and accompanying warrants to an accredited investor.

ZIVO BIOSCIENCE, INC. announced that its shareholders approved all three proposals at the annual meeting held on June 9, 2025, including the election of two Class III directors, the ratification of its independent public accounting firm, and the advisory approval of executive compensation.

Zivo Bioscience issued 191,698 shares of common stock through private sales, restricted stock grants, and an exchange program.

Zivo Bioscience is set to cancel participation agreements with accredited investors, exchanging their rights to revenue share and buy-out options for shares of common stock.

ZIVO Bioscience, Inc. has officially changed its principal executive office location effective January 6, 2025.

Zivo Bioscience has entered into debt settlement agreements with three creditors, issuing promissory notes totaling $277,254.38 to restructure existing debt.

Zivo Bioscience sold 169,022 shares of common stock to accredited investors between August 22 and October 17, 2024, raising capital through a private placement.

ZIVO Bioscience has appointed Laith Yaldoo to its Board of Directors, increasing the board size from four to five members.

Zivo Bioscience held its annual shareholder meeting on June 11, 2024, where shareholders elected a director, ratified the appointment of an auditor, and approved executive compensation.

Zivo Bioscience files an amendment to correct a typographical error in the date of a stock award for unpaid director fees.

Zivo Bioscience has adopted a new equity incentive plan for non-employee directors, amended its compensation policy, and executed stock option replacement programs for both directors and employees.

Zivo Bioscience's common stock and warrants will be delisted from Nasdaq and will continue trading on the OTCQB market.

Zivo Bioscience sold 174,145 shares of its common stock to accredited investors in a private placement between January 4, 2024 and January 16, 2024.